SEARCH

SEARCH BY CITATION

References

  • 1
    Heart Disease and Stroke Statistics – 2004 Update. Dallas, TX: American Heart Association; 2003.
  • 2
    Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21S30.
  • 3
    Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:15411547.
  • 4
    Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263266.
  • 5
    Riegger GAJ, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982;72:4952.
  • 6
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:17241729.
  • 7
    Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:13851390.
  • 8
    Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol. 1986;58:295299.
  • 9
    Pruszczynski W, Vahanian A, Ardaillou R. Role of antidiuretic hormone in impaired water excretion in patients with congestive heart failure. J Clin Endocrinol Metab. 1984;58:599605.
  • 10
    Bichet DG, Kortas C, Mettauer B, et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 1986;29:11881196.
  • 11
    Gheorghiade M, Gattis WA, O’connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:19631971.
  • 12
    Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:7178.
  • 13
    Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459466.
  • 14
    Goldsmith SR. Baroreflex control of vasopressin secretion in normal humans. In: CowleyAW, LiardJ-F, AusielloDA, eds. Vasopressin: Cellular and Integrative Functions, New York: Raven Press; 1988;389397.
  • 15
    Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J Card Fail. 1999;5:347356.
  • 16
    Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29:19.
  • 17
    Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999;10:647663.
  • 18
    Hirsch AT, Dzau VJ, Majzoub JA, Creager MA. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest. 1989;84:418426.
  • 19
    Kaufmann JE, Oksche A, Wollheim CB, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106:107116.
  • 20
    Creager MA, Faxon DP, Cutler SS, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol. 1986;7:758765.
  • 21
    Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860867.
  • 22
    Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol. 1998;449:439443.
  • 23
    Tahara A, Tomura Y, Wada KI, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301308.
  • 24
    Tomura Y, Tahara A, Tsukada J, et al. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol. 1999;26:399403.
  • 25
    Risvanis J, Naitoh M, Johnston CI, Burrell LM. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur J Pharmacol. 1999;381:2330.
  • 26
    Yatsu T, Tomura Y, Tahara A, et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol. 1997;321:225230.
  • 27
    Serradeil-Le GC. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev. 2001;19:201214.
  • 28
    Zeltser D, Rosansky S, Van RH, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447457.
  • 29
    Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337:2836.
  • 30
    Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:21452152.
  • 31
    Ghali JK, Verbalis JG, Gross P, et al. Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia [abstract]. Am Coll Cardiol. 2006; 47:816817.
  • 32
    Ghali JK, Yan B, McNutt B. Conivaptan, a vasopressin-receptor antagonist, for the treatment of hyponatremia in patients with and without underlying heart failure [abstract]. Heart Fail Soc. 2008;14(suppl 1):236.
  • 33
    Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:20992112.
  • 34
    Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:13191331.